PGEN

Precigen's stock experienced significant events in the past six months, including strong fiscal Q2 2026 financial performance on August 4, 2026, reporting EPS of $0.05, its first profitable quarter since 2020 with $55.0 million in total revenues, largely driven by PAPZIMEOS sales, which contributed to a 50% stock gain. PAPZIMEOS also demonstrated accelerating commercial momentum, generating $53.1 million in net revenue in Q2 2026, and received seven-year market exclusivity from the FDA. On September 21, 2026, Precigen received an FDA "platform technology designation" for its AdenoVerse platform, validating its versatility. Analysts maintained a "Moderate Buy" consensus rating for PGEN, with an average price target of $13.67, and H.C. Wainwright raised its target to $18.00. The company projects to reach cash flow break-even by year-end 2026, funded by its current cash and PAPZIMEOS sales. However, Precigen shares slid on October 5, 2026, due to a broader biotech sector rout, weak trial results from Amgen, rising oil prices, and Federal Reserve rate-hike fears. Earlier, on March 26, 2026, PGEN shares surged approximately 30% following strong Q1 2026 revenue guidance exceeding $18 million, a 429% sequential increase, driven by the rapid commercial uptake of PAPZIMEOS.